JP2022529343A - ウイルス感染および細菌感染の治療のための新規ｍｅｋ阻害剤 - Google Patents

ウイルス感染および細菌感染の治療のための新規ｍｅｋ阻害剤 Download PDF

Info

Publication number
JP2022529343A
JP2022529343A JP2021561625A JP2021561625A JP2022529343A JP 2022529343 A JP2022529343 A JP 2022529343A JP 2021561625 A JP2021561625 A JP 2021561625A JP 2021561625 A JP2021561625 A JP 2021561625A JP 2022529343 A JP2022529343 A JP 2022529343A
Authority
JP
Japan
Prior art keywords
virus
pharmaceutically acceptable
acceptable salt
use according
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021561625A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022529343A5 (https=
Inventor
オリバー プランツ
Original Assignee
アトリバ セラピューティクス ゲーエムベーハー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アトリバ セラピューティクス ゲーエムベーハー filed Critical アトリバ セラピューティクス ゲーエムベーハー
Publication of JP2022529343A publication Critical patent/JP2022529343A/ja
Publication of JP2022529343A5 publication Critical patent/JP2022529343A5/ja
Priority to JP2025083321A priority Critical patent/JP2025124703A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2021561625A 2019-04-16 2020-04-16 ウイルス感染および細菌感染の治療のための新規ｍｅｋ阻害剤 Pending JP2022529343A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025083321A JP2025124703A (ja) 2019-04-16 2025-05-19 ウイルス感染および細菌感染の治療のための新規ｍｅｋ阻害剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
LULU101183 2019-04-16
LU101183A LU101183B1 (en) 2019-04-16 2019-04-16 Novel mek-inhibitor for the treatment of viral and bacterial infections
PCT/EP2020/060692 WO2020212478A1 (en) 2019-04-16 2020-04-16 Novel mek-inhibitor for the treatment of viral and bacterial infections

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025083321A Division JP2025124703A (ja) 2019-04-16 2025-05-19 ウイルス感染および細菌感染の治療のための新規ｍｅｋ阻害剤

Publications (2)

Publication Number Publication Date
JP2022529343A true JP2022529343A (ja) 2022-06-21
JP2022529343A5 JP2022529343A5 (https=) 2023-04-21

Family

ID=66554457

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021561625A Pending JP2022529343A (ja) 2019-04-16 2020-04-16 ウイルス感染および細菌感染の治療のための新規ｍｅｋ阻害剤
JP2025083321A Pending JP2025124703A (ja) 2019-04-16 2025-05-19 ウイルス感染および細菌感染の治療のための新規ｍｅｋ阻害剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025083321A Pending JP2025124703A (ja) 2019-04-16 2025-05-19 ウイルス感染および細菌感染の治療のための新規ｍｅｋ阻害剤

Country Status (13)

Country Link
US (1) US12350244B2 (https=)
EP (1) EP3955908B1 (https=)
JP (2) JP2022529343A (https=)
KR (1) KR20210153642A (https=)
CN (1) CN114007598A (https=)
AU (1) AU2020258002B2 (https=)
BR (1) BR112021020605A2 (https=)
CA (1) CA3136171A1 (https=)
EA (1) EA202192454A1 (https=)
ES (1) ES3012533T3 (https=)
LU (1) LU101183B1 (https=)
MX (1) MX2021012604A (https=)
WO (1) WO2020212478A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023526836A (ja) * 2020-05-20 2023-06-23 アトリバ セラピューティクス ゲーエムベーハー コロナウイルス感染症および／またはｃｏｖｉｄ－１９サイトカインストームの処置または予防のためのｍｅｋ阻害剤

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4186500A1 (en) * 2021-11-24 2023-05-31 Atriva Therapeutics GmbH Mek inhibitors for the prevention and treatment of long covid syndrome
WO2024042050A1 (en) * 2022-08-22 2024-02-29 Atriva Therapeutics Gmbh Use of mek1/2 inhibitors to synergistically potentiate the antiviral effect of direct-acting anti-coronavirus drugs
CN119931962B (zh) * 2025-04-07 2025-08-05 北京华诺泰生物医药科技有限公司 一种人偏肺病毒的培养方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002534381A (ja) * 1999-01-07 2002-10-15 ワーナー−ランバート・カンパニー Ｍｅｋ阻害剤を用いた抗ウィルス法
JP2003504400A (ja) * 1999-07-16 2003-02-04 ワーナー−ランバート・カンパニー Ｍｅｋ阻害剤を用いた慢性痛の治療方法
JP2015534562A (ja) * 2012-10-08 2015-12-03 シュテファン プレシュカ ウイルス疾患の処置におけるｍｅｋ阻害物質
JP2017515910A (ja) * 2014-05-16 2017-06-15 アトリバ セラピューティクス ゲーエムベーハー インフルエンザウイルスおよび黄色ブドウ球菌の重感染に対する新規の抗感染戦略

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10017480A1 (de) 2000-04-07 2001-10-11 Transmit Technologietransfer Verwendung von Substanzen, die als MEK Inhibitor wirken, zur Herstellung eines Arneimittels gegen DNA- und RNA-Viren
EP3973960B1 (en) * 2017-10-17 2025-09-03 Atriva Therapeutics GmbH Novel mek-inhibitor for the treatment of viral and bacterial infections
KR20220074869A (ko) * 2019-08-27 2022-06-03 아트리바 테라퓨틱스 게엠베하 Mek 억제제와 캡-의존성 엔도뉴클레아제 억제제의 조합
JP7802365B2 (ja) * 2019-10-08 2026-01-20 アトリバ セラピューティクス ゲーエムベーハー ハンタウイルス感染症の処置のためのｍｅｋ阻害剤
EP3912623B1 (en) * 2020-05-20 2024-07-31 Atriva Therapeutics GmbH Pd-0184264 for the treatment of coronavirus infections and/or covid-19 cytokine storm

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002534381A (ja) * 1999-01-07 2002-10-15 ワーナー−ランバート・カンパニー Ｍｅｋ阻害剤を用いた抗ウィルス法
JP2003504400A (ja) * 1999-07-16 2003-02-04 ワーナー−ランバート・カンパニー Ｍｅｋ阻害剤を用いた慢性痛の治療方法
JP2015534562A (ja) * 2012-10-08 2015-12-03 シュテファン プレシュカ ウイルス疾患の処置におけるｍｅｋ阻害物質
JP2017515910A (ja) * 2014-05-16 2017-06-15 アトリバ セラピューティクス ゲーエムベーハー インフルエンザウイルスおよび黄色ブドウ球菌の重感染に対する新規の抗感染戦略

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
"５．新型インフルエンザ（パンデミックＨ１Ｎ１ ２００９）の現状", 日本内科学会雑誌, vol. 99巻臨時増刊号, JPN6025000723, 2010, pages 64 - 69, ISSN: 0005692478 *
"Antiviral efficacy against influenza virus and pharmacokinetic analysis of a novel MEK-inhibitor, AT", ANTIVIRAL RESEARCH, vol. 178, JPN6024014412, 15 April 2020 (2020-04-15), pages 1 - 14, ISSN: 0005304941 *
"Metabolic conversion of CI-1040 turns a cellular MEK-inhibitor into an antibacterial compound", SCIENTIFIC REPORTS, vol. 8:9114, JPN6024014415, 14 June 2018 (2018-06-14), pages 1 - 11, ISSN: 0005692476 *
"PD0184264, an active metabolite of the MEK-inhibitor CI-1040 shows superior pharmacokinetics and ant", 6TH INTERNATIONAL INFLUENZA MEETING, JPN6024014414, September 2018 (2018-09-01), pages 112, ISSN: 0005692477 *
"The MEK-inhibitor CI-1040 displays a broad anti-influenza virus activity in vitro and provides a pro", ANTIVIRAL RESEARCH, vol. 142, JPN6024014413, 2017, pages 178 - 184, ISSN: 0005304940 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023526836A (ja) * 2020-05-20 2023-06-23 アトリバ セラピューティクス ゲーエムベーハー コロナウイルス感染症および／またはｃｏｖｉｄ－１９サイトカインストームの処置または予防のためのｍｅｋ阻害剤

Also Published As

Publication number Publication date
JP2025124703A (ja) 2025-08-26
KR20210153642A (ko) 2021-12-17
EA202192454A1 (ru) 2022-03-22
LU101183B1 (en) 2020-10-16
CA3136171A1 (en) 2020-10-22
CN114007598A (zh) 2022-02-01
US20220193017A1 (en) 2022-06-23
AU2020258002B2 (en) 2025-12-18
AU2020258002A1 (en) 2021-11-18
ES3012533T3 (en) 2025-04-09
BR112021020605A2 (pt) 2021-12-07
EP3955908A1 (en) 2022-02-23
MX2021012604A (es) 2021-11-12
US12350244B2 (en) 2025-07-08
WO2020212478A1 (en) 2020-10-22
EP3955908C0 (en) 2025-01-22
EP3955908B1 (en) 2025-01-22

Similar Documents

Publication Publication Date Title
JP7618276B2 (ja) ウイルス感染および細菌感染の処置のための新規ｍｅｋ阻害剤
AU2020256326B2 (en) Novel Anti-Infective Strategy Against Influenza Virus And S.aureus Coinfections
JP2025124703A (ja) ウイルス感染および細菌感染の治療のための新規ｍｅｋ阻害剤
EA047137B1 (ru) Новый ингибитор mek для лечения вирусных и бактериальных инфекций
EA042391B1 (ru) Новый ингибитор mek для лечения вирусных и бактериальных инфекций
BR112020007442B1 (pt) Uso de PD-0184264 ou um sal farmaceuticamente aceitável do mesmo e composições farmacêuticas
HK40029715A (en) Novel mek-inhibitor for the treatment of viral and bacterial infections

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211208

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230413

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230413

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20231027

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240416

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240704

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241016

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250120

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250519

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250716